Improved survival with recent post-transplant lymphoproliferative disorder (PTLD) in children with kidney transplants

American Journal of Transplantation

Volumn 11, Issue 4, 2011, Pages 751-758

  Dharnidharka, V R ^a   Martz, K L ^b   Stablein, D M ^b   Benfield, M R ^c  

^a UNIVERSITY OF FLORIDA   (United States)

^b EMMES CORPORATION   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Kidney transplant; pediatric; post transplant lymphoproliferative disorder

Indexed keywords

ADOLESCENT; ARTICLE; CHILD; FEMALE; FOLLOW UP; GRAFT SURVIVAL; HUMAN; IMPLANT REGISTRY; KIDNEY GRAFT; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE COMPLICATION; POSTTRANSPLANTATION LYMPHOPROLIFERATIVE DISEASE; PRESCHOOL CHILD; PRIORITY JOURNAL; QUESTIONNAIRE; RECURRENT DISEASE; SCHOOL CHILD; SURGICAL MORTALITY; SURVIVAL;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT SURVIVAL; HUMANS; INFANT; INFANT, NEWBORN; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; MALE; POSTOPERATIVE COMPLICATIONS; QUESTIONNAIRES; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 79953254320     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03470.x     Document Type: Article

References (29)

1. Dharnidharka VR,. Epidemiology of PTLD. In:, Dharnidharka VR, Green M, Webber SA, eds. Post-transplant lymphoproliferative disorders. Berlin: Springer-Verlag, 2009: 17-28.
2. Murray JE, Wilson RE, Tilney NL, et al,. Five years' experience in renal transplantation with immunosuppressive drugs: Survival, function, complications, and the role of lymphocyte depletion by thoracic duct fistula. Ann Surg 1968; 168: 416-435. Discussion by Starzl TE, p. 33- 34.
3. Hebert D, Sullivan EK,. Malignancy and post transplant lymphoproliferative disorder (PTLD) in pediatric renal transplant recipients: A report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatric Transplant 1998; 2 (1 Suppl): 107:57A.
4. McDonald RA, Smith JM, Ho M, et al,. Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids. Am J Transplant 2008; 8: 984-989. (Pubitemid 351537758)
5. Srivastava T, Zwick DL, Rothberg PG, Warady BA,. Posttransplant lymphoproliferative disorder in pediatric renal transplantation. Pediatr Nephrol 1999; 13: 748-754.
6. Caillard S, Lelong C, Pessione F, Moulin B,. Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: Report of 230 cases from the French Registry. Am J Transplant 2006; 6: 2735-2742. (Pubitemid 44571695)
7. Trofe J, Buell JF, Beebe TM, et al,. Analysis of factors that influence survival with post-transplant lymphoproliferative disorder in renal transplant recipients: The Israel Penn International Transplant Tumor Registry experience. Am J Transplant 2005; 5 (4 Pt 1): 775-780. (Pubitemid 40461287)
8. Tsai DE, Hardy CL, Tomaszewski JE, et al,. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: Analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation 2001; 71: 1076-1088. (Pubitemid 32448822)
9. Ghobrial IM, Habermann TM, Ristow KM, et al,. Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era. Leuk Lymphoma 2005; 46: 191-196. (Pubitemid 40185948)
10. Leblond V, Dhedin N, Mamzer Bruneel MF, et al,. Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. J Clin Oncol 2001; 19: 772-778. (Pubitemid 32119092)
11. Dharnidharka VR, Ho PL, Stablein DM, Harmon WE, Tejani AH,. Mycophenolate, tacrolimus and post-transplant lymphoproliferative disorder: A report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Transplant 2002; 6: 396-399. (Pubitemid 35265190)
12. Dharnidharka VR, Sullivan EK, Stablein DM, Tejani AH, Harmon WE,. Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: A report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Transplantation 2001; 71: 1065-1068. (Pubitemid 32448820)
13. Dharnidharka VR, Tejani AH, Ho PL, Harmon WE,. Post-transplant lymphoproliferative disorder in the United States: Young Caucasian males are at highest risk. Am J Transplant 2002; 2: 993-998. (Pubitemid 36330232)
14. Allen UD, Farkas G, Hebert D, et al,. Risk factors for post-transplant lymphoproliferative disorder in pediatric patients: A case-control study. Pediatr Transplant 2005; 9: 450-455. (Pubitemid 41153264)
15. Webber SA, Naftel DC, Fricker FJ, et al,. Lymphoproliferative disorders after paediatric heart transplantation: A multi-institutional study. Lancet 2006; 367: 233-239. (Pubitemid 43107668)
16. Caillard S, Dharnidharka V, Agodoa L, Bohen E, Abbott K,. Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 2005; 80: 1233-1243. (Pubitemid 41746802)
17. Opelz G, Dohler B,. Lymphomas after solid organ transplantation: A collaborative transplant study report. Am J Transplant 2004; 4: 222-230. (Pubitemid 38248525)
18. Patel H, Vogl DT, Aqui N, et al,. Posttransplant lymphoproliferative disorder in adult liver transplant recipients: A report of seventeen cases. Leuk Lymphoma 2007; 48: 885-891. (Pubitemid 47161559)
19. Saadat A, Einollahi B, Ahmadzad-Asl MA, et al,. Posttransplantation lymphoproliferative disorders in renal transplant recipients: Report of over 20 years of experience. Transplant Proc 2007; 39: 1071-1073. (Pubitemid 46764891)
20. Cacciarelli TV, Green M, Jaffe R, et al,. Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy. Transplantation 1998; 66: 1047-1052. (Pubitemid 28513385)
21. Duvoux C, Pageaux GP, Vanlemmens C, et al,. Risk factors for lymphoproliferative disorders after liver transplantation in adults: An analysis of 480 patients. Transplantation 2002; 74: 1103-1109. (Pubitemid 35216103)
22. Fernandez MC, Bes D, De Davila M, et al,. Post-transplant lymphoproliferative disorder after pediatric liver transplantation: Characteristics and outcome. Pediatr Transplant 2009; 13: 307-310.
23. Boyle GJ, Michaels MG, Webber SA, et al,. Posttransplantation lymphoproliferative disorders in pediatric thoracic organ recipients. J Pediatr 1997; 131: 309-313. (Pubitemid 27495257)
24. Newell KA, Alonso EM, Whitington PF, et al,. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression. Transplantation 1996; 62: 370-375. (Pubitemid 26277344)
25. Younes BS, McDiarmid SV, Martin MG, et al,. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients. Transplantation 2000; 70: 94-99. (Pubitemid 30490758)
26. Buell JF, Gross TG, Hanaway MJ, et al,. Posttransplant lymphoproliferative disorder: Significance of central nervous system involvement. Transplant Proc 2005; 37: 954-955. (Pubitemid 40590756)
27. Birkeland SA, Hamilton-Dutoit S, Bendtzen K,. Long-term follow-up of kidney transplant patients with posttransplant lymphoproliferative disorder: Duration of posttransplant lymphoproliferative disorder-induced operational graft tolerance, interleukin-18 course, and results of retransplantation. Transplantation 2003; 76: 153-158. (Pubitemid 36877129)
28. Karras A, Thervet E, Le Meur Y, Baudet-Bonneville V, Kessler M, Legendre C,. Successful renal retransplantation after post-transplant lymphoproliferative disease. Am J Transplant 2004; 4: 1904-1909. (Pubitemid 39434453)
29. Johnson J, Kerecuk L, Harrison M, Taylor JO, Odell E,. Epstein-Barr virus-associated lymphoproliferative disease in oral cavity in a renal transplant recipient: A case report. Pediatr Transplant 2007; 11: 340-344. (Pubitemid 46570156)